Skip to Content
Merck
CN

186066

3-Amino-4-methoxybenzoic acid

≥98%

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Linear Formula:
H2NC6H3(OCH3)CO2H
CAS Number:
Molecular Weight:
167.16
UNSPSC Code:
12352200
PubChem Substance ID:
EC Number:
220-634-3
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

3-Amino-4-methoxybenzoic acid, ≥98%

InChI key

FDGAEAYZQQCBRN-UHFFFAOYSA-N

InChI

1S/C8H9NO3/c1-12-7-3-2-5(8(10)11)4-6(7)9/h2-4H,9H2,1H3,(H,10,11)

SMILES string

COc1ccc(cc1N)C(O)=O

assay

≥98%

mp

208-210 °C (lit.)

application(s)

peptide synthesis

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A-Long Cui et al.
Drug design, development and therapy, 14, 3723-3729 (2020-09-29)
Hepatitis B virus (HBV) is a global health concern that can cause acute and chronic liver diseases. Thus, there is an urgent need to research novel anti-HBV agents. Our previous reports show that N-phenylbenzamide derivatives exert broad-spectrum antiviral effects against
Shanglin Chen et al.
Journal of controlled release : official journal of the Controlled Release Society, 320, 73-82 (2020-01-21)
Cardiac tissue engineering is of particular importance in the combination of contracting cells with a biomaterial scaffold, which serves as a cell-delivery construct, to replace cardiomyocytes (CMs) that are lost as a result of an infarction, to restore heart function.
Zhao An et al.
Theranostics, 11(8), 3948-3960 (2021-03-06)
Background: Pacemaker implantation is currently used in patients with symptomatic bradycardia. Since a pacemaker is a lifetime therapeutic device, its energy consumption contributes to battery exhaustion, along with its voltage stimulation resulting in local fibrosis and greater resistance, which are

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service